Durable Clinical Outcomes With Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS II Patients (TOPAZ Study) (P6.369)
Year: 2018
Type: article
Source: Neurology
Institutions: Missouri Baptist Medical Center, Amiri Hospital, Hôpital Purpan, Université de Toulouse, Griffith University, Heinrich Heine University Düsseldorf, Charles University, National Cancer Center, National Cancer Center Hospital, Hospital Clínico San Carlos, Medical University of Lodz, Université de Lille, University of Cambridge
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Keywords: alemtuzumab, relapsing-remitting multiple sclerosis, long-term efficacy, retreatment, annualized relapse rate, disability progression, no evidence of disease activity, disease-modifying therapy, treatment discontinuation, infusion reactions, infection, interferon beta-1a, MRI activity, Expanded Disability Status Scale
Open Access status: closed
OpenAlex ID: W2883116374
